Browse drugs

…negative controls. Stably BE-expressing cells were cultured +/- IFN-β for 48hr and then positively selected for surface expression of…

… in combination-treated tumor tissues was increased compared to Atezolizumab treatment alone.Conclusions Thus, shutting down EpCAM signaling…

…1 expression ~3-fold. In syngeneic models (MC38, B16F10, LLC1), CNFX887-Fc monotherapy slowed tumor growth by 2.0-2.5x, remodeling the TME…

… with clinical outcomes ( figure 1). The PDTOs are sensitive to 5-FU, oxaliplatin, irinotecan and their combination (figure 2). Howe…

…gy for solid tumors, exemplified by the recent FDA approvals of tebentafusp and afamitresgene autoleucel, which target Class I peptide-HLA …

…cy is still limited without appropriate patient stratification. HM16390 is an IL-2 analog engineered with enhanced IL-2Rβ binding and f…

…treicher H, Sondak VK, Kirkwood JM. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resecte…

…d CellCage™ Enclosures (CCEs) and treated with EGFR inhibitors (Olmutinib) or antibody drug conjugate (Cetuximab-MMAE) ( figure 1). Conta…

…ons in the expansion or treatment phase enhanced the potency of CAR-T.Conclusions Hence we created a co-culture of a vessel and cance…

… glycolytic capacity. Furthermore, in the presence of exogenous TGF-β, MED12 KO CAR NK cells showed greater resistance to TGF-β inhib…

…findings were orthogonally validated using a cell-free ELISA of HACA. Several B-cell receptor clonotypes emerged after GD2-CAR T-cel…

… expression of immune checkpoint molecules and target antigens. B7-H3 emerged as particularly promising due to its uniform expression…